Rayner, MLD;
Grillo, A;
Williams, G;
Tawfik, E;
Zhang, T;
Volitaki, C;
Craig, DQM;
... Phillips, J; + view all
(2020)
Controlled local release of PPARγ agonists from biomaterials to treat peripheral nerve injury.
Journal of Neural Engineering
10.1088/1741-2552/aba7cc.
(In press).
Preview |
Text
Rayner+et+al_2020_J._Neural_Eng._10.1088_1741-2552_aba7cc.pdf - Accepted Version Download (2MB) | Preview |
Abstract
Objective: Poor clinical outcomes following peripheral nerve injury (PNI) are partly attributable to the limited rate of neuronal regeneration. Despite numerous potential drug candidates demonstrating positive effects on nerve regeneration rate in preclinical models, no drugs are routinely used to improve restoration of function in clinical practice. A key challenge associated with clinical adoption of drug treatments in nerve injured patients is the requirement for sustained administration of doses associated with undesirable systemic side-effects. Local controlled-release drug delivery systems could potentially address this challenge, particularly through the use of biomaterials that can be implanted at the repair site during the microsurgical repair procedure. Approach: In order to test this concept, this study used various biomaterials to deliver ibuprofen sodium or sulindac sulfide locally in a controlled manner in a rat sciatic nerve injury model. Following characterisation of release parameters in vitro, ethylene vinyl acetate (EVA) tubes or polylactic-co-glycolic acid (PLGA) wraps, loaded with ibuprofen sodium or sulindac sulfide, were placed around directly-repaired nerve transection or nerve crush injuries in rats. Main results: Ibuprofen sodium, but not sulindac sulfide caused an increase in neurites in distal nerve segments and improvements in functional recovery in comparison to controls with no drug treatment. Significance: This study showed for the first time that local delivery of ibuprofen sodium using biomaterials improves neurite growth and functional recovery following PNI and provides the basis for future development of drug-loaded biomaterials suitable for clinical translation.
Archive Staff Only
 |
View Item |
